Premature Adrenarche: Essential Knowledge for Endocrinologists
Premature adrenarche (PA) is a benign diagnosis of exclusion characterized by early appearance of pubic/axillary hair before age 8 in girls or 9 in boys, requiring systematic evaluation to exclude virilizing disorders, particularly nonclassic congenital adrenal hyperplasia (NCCAH), which accounts for 5-10% of cases presenting with premature pubarche. 1, 2
Definition and Clinical Presentation
PA represents early activation of the zona reticularis with elevated adrenal androgens (particularly DHEAS) appropriate for early puberty but advanced for chronological age. Clinical manifestations include:
- Pubic or axillary hair (93.8% of cases) 3
- Adult-type body odor, acne, oily skin/hair 4
- Accelerated linear growth with proportionate bone age advancement (typically 0.3-3.2 years ahead) 4, 2
- Prepubertal breast development in girls (Tanner I) and testicular volume <4 mL in boys 3
Diagnostic Evaluation Algorithm
First-Line Assessment
Measure basal androgens:
- DHEAS (primary marker)
- Androstenedione
- Testosterone
- 17-hydroxyprogesterone (17-OHP)
Obtain bone age radiograph
Document growth velocity and height relative to mid-parental target
Critical Thresholds and Red Flags
Basal 17-OHP >6 nmol/L mandates ACTH stimulation testing to exclude NCCAH 3. This identifies approximately 5.7% of cases with 21-hydroxylase deficiency that would otherwise be missed 3.
"Exaggerated adrenarche" (DHEAS >6 μmol/L, above pubertal range) occurs in 9.1% of cases and warrants closer metabolic monitoring 3.
When to Pursue Further Testing
Proceed with ACTH stimulation test (250 μg Synacthen IM, measure at 0,30,60 minutes) if:
- Basal 17-OHP >6 nmol/L
- Rapid progression of virilization
- Bone age advancement compromising height potential
- Clinical features suggesting tumor (hypertension, palpable mass, rapid onset)
Adrenal imaging (ultrasound or CT) is reserved for atypical presentations suggesting tumor 5. Routine imaging is not recommended as adrenal masses occur in 1-4% of normal individuals 5.
Metabolic Considerations
PA carries significant metabolic implications that distinguish it from simple early maturation:
Insulin Resistance Profile
Children with PA demonstrate:
- Higher fasting insulin levels (mean difference 15.04 pmol/L vs controls) 6
- Elevated BMI-SDS at presentation 6
- Association with low birth weight in some populations 1, 7
One-third of prepubertal minority girls (African-American, Caribbean Hispanic) with PA exhibit marked hyperandrogenism and insulin resistance 8. These patients show ACTH-stimulated 17-hydroxypregnenolone levels >2 SD above normal early pubertal girls 8.
Long-Term Risks
Follow-up studies reveal that girls with PA and insulin resistance at presentation continue to manifest:
- Obesity
- Persistent insulin resistance
- Hyperandrogenism with irregular menses, hirsutism, acne
- Possible progression to polycystic ovary syndrome 8, 7
However, fasting glucose, HOMA-IR, and lipid profiles typically remain normal at initial presentation 6, making these less useful screening tools.
Treatment Decisions
When NOT to Treat
The majority of PA cases require no pharmacologic intervention 5, 1. Specifically, avoid treatment in:
- Asymptomatic children with isolated early pubarche
- Normal growth velocity without excessive bone age advancement
- Absence of insulin resistance markers
When to Consider Treatment
Treat children with inappropriately early onset AND rapid progression of pubarche with accelerated bone maturation that threatens adult height 5.
Glucocorticoid Therapy
For glucocorticoid-suppressible hyperandrogenism (predominantly adrenal source):
- Prednisone 5-7.5 mg or dexamethasone 0.25-0.5 mg daily after supper for 2-3 months 9
- Reassess androgen levels; if normalized, reduce to prednisone 5 mg or dexamethasone 0.25 mg 9
- Early treatment (1-2 years) may yield long-term remission and prevent metabolic/ovulatory disorders 9
- Monitor closely for iatrogenic Cushing's syndrome 5
Metformin for Insulin Resistance
In PA patients with low birth weight history and documented insulin resistance, consider metformin on a case-by-case basis 1. This represents off-label use but addresses the underlying metabolic dysfunction.
Predictors of Progression
Risk Factors for Central Precocious Puberty
Approximately 13-15% of PA cases progress to central precocious puberty (CPP). Key predictors include:
- Corrected height SDS >1.8 at presentation (ROC cutoff) 10
- BA/CA ratio >1.2 10
- Higher baseline bone age SDS 10
Notably, baseline DHEAS concentration does NOT predict progression to CPP or final height outcomes 10, despite reflecting adrenal maturation.
Final Height Outcomes
Baseline corrected height SDS is the strongest predictor of final height (p<0.001), while BMI-SDS shows negative association (p=0.003) 10. This emphasizes the importance of early auxological assessment.
Common Pitfalls to Avoid
Prescribing oral contraceptives for "menstrual regulation" without determining androgen source - This treats symptoms while missing underlying pathology and metabolic risk 9
Assuming normal DHEAS excludes significant pathology - 5.7% have NCCAH despite presentation as "simple" PA 3
Ordering routine bone density scans - Standard GC therapy (10-20 mg/m²) does not decrease BMD in children when normalized for height 5
Treating all cases pharmacologically - Most PA is benign and self-limited 5, 1
Failing to screen for insulin resistance in high-risk populations - Particularly minority girls and those with low birth weight history 8
Monitoring Strategy
For diagnosed PA without treatment:
- Serial auxology every 3-6 months (height velocity, weight, BMI)
- Repeat bone age annually if initially advanced
- Screen for insulin resistance (fasting glucose/insulin) in high-risk patients
- Assess for progression to CPP (breast development, testicular enlargement)
- Monitor for metabolic syndrome components during adolescence
Early identification and intervention in at-risk children may prevent complications including type 2 diabetes, dyslipidemia, and PCOS 8, 7.